Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

S. Finn, Richard; Ikeda, Masafumi; X. Zhu, Andrew; W. Sung, Max; David Baron, Ari; Kudo, Masatoshi; Okusaka, Takuji; Kobayashi, Masahiro; Kumada, Hiromitsu; Kaneko, Shuichi; Pracht, Marc; G Mamontov, K.; Meyer, Tim; Kubota, Tomoki; E. Dutcus, Corina; Saito, Kenichi; B. Siegel, Abby; Dubrovsky, Leonid; Mody, Kalgi; M. Llovet, Josep

doi:10.1200/jco.20.00808

Public

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Published in Journal of Clinical Oncology • Jul 27, 2020

Authors:

Richard S. Finn

Masafumi Ikeda

Andrew X. Zhu

Abstract

PURPOSE: The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study of lenvat...

Subject

Lenvatinib

Medicine

Pembrolizumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!